A woman who lost over two stone in just four months has revealed how she was able to quit weight-loss jabs for good by 'micro ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

CINCINNATI — U.S. Customs and Border Protection (CBP) and the U.S. Food and Drug Administration (FDA) at the port of ...

Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for ...

Novo Nordisk saw sales growth for its diabetes and obesity care segment slow in the first half of 2025, confirming investor ...

The number of people taking weight-loss injections is exploding. With more and more men going “on the needle”, here’s what ...

If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues ...

Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...

Indian pharmaceutical companies are preparing to launch generic versions of Novo Nordisk's weight-loss drug, semaglutide, potentially reducing its price by up to 80%.

Suzanne Hall, who is on the NHS waiting list for bariatric surgery, said she feels let down by the NHS over the delayed ...